Tilman Schneider-Hohendorf

20PUBLICATIONS
91CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Nanotoxicology, health and safetyGene and molecular therapyRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Aug 26, 2026
Distinct Multiomic Signatures of Environmental Exposure Drive Immune Dysregulation and Disease Activity in Early Multiple Sclerosis.

|Jan 23, 2026
Confined B-Cell Reconstruction and High T-Cell Clonality Define Clinical Response to Cladribine Treatment.

Tilman Schneider-Hohendorf, Maria Eveslage, Timo Wirth

|Sep 24, 2025
Annual 12-Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition.

Regina Berkovich, Tilman Schneider-Hohendorf, Eric Baetscher

|Jul 18, 2024
Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation.

Tilman Schneider-Hohendorf, Christian Wünsch, Simon Falk

|Dec 27, 2022
Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound.

Claudia Janoschka, Maren Lindner, Nils Koppers

|Nov 30, 2022
A single-cell analysis framework allows for characterization of CSF leukocytes and their tissue of origin in multiple sclerosis.

Patrick Ostkamp, Marie Deffner, Andreas Schulte-Mecklenbeck

Pageof 4

Frequent Collaborators

18 joint publications

Nicholas Schwab

8 joint publications

Andreas Schulte-Mecklenbeck

6 joint publications

Catharina C Gross

5 joint publications

Luisa Klotz